Efficacy and Safety Evaluation of Neobianacid® in GERD and EPS

GERD Clinical Trial

Official title:

Relief of Heartburn and Epigastric Pain Comparing Neobianacid® With Omeprazole: a Randomized, Double Blind, Double Dummy, Reference Product Controlled, Parallel Group, Non-inferiority Clinical Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03238534
• Other study ID #: ABO-NB-15
• Status: Completed
• Phase: Phase 4
• Start date: September 12, 2017
• Est. completion date: September 3, 2021

Study information

• Verified date: December 2021
• Source: Aboca Spa Societa' Agricola
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Comparison of Neobianacid® clinical efficacy to omeprazole in relief of heartburn or epigastric pain

Description:

Comparison of heartburn or epigastric pain severity following administration of Neobianacid® (Group B) or omeprazole (Group A) from day 0 to day 27. An ad-hoc placebo will be also administered in both treatment arms. Then, a following phase (day 28-55) will follows in which Neobianacid® will be administered (on demand) to both treatment arms.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 275
• Est. completion date: September 3, 2021
• Est. primary completion date: September 3, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Male and female patients 18 - 70 years old (inclusive).

2. Patients presenting one or both the 2 following conditions:

• Patients presenting heartburn who have been already diagnosed with uncomplicated gastroesophageal reflux disease (GERD) or whose symptoms are consistent with a clinical diagnosis of uncomplicated GERD.

• Patients who have been already diagnosed with uncomplicated Epigastric Pain Syndrome (EPS) or whose symptoms are consistent with a clinical diagnosis of uncomplicated EPS according to Rome III criteria.

3. A gastroscopy is to be performed if not already performed during the previous 3 years and the symptomatology is unchanged.

4. Patients having a VAS score = 30mm and = 70mm (VAS related to heartburn/ epigastric pain) for at least 6 out of 14 days preceding the screening visit.

5. Postmenopausal women i.e. women who have not experienced a menstrual bleed for a minimum of 12 months or women who have undergone surgical sterilization (tubal closure or ovaries removal). Otherwise, necessity for women of childbearing potential to follow a reliable contraceptive treatment.

6. Ability of the patients (in the Investigator's opinion) to comprehend the full nature and purpose of the study including possible risks and side effects.

7. Patients who agree not to alter their diet in any way for the duration of the trial and to maintain it at steady state.

8. Patients who agree not to make any major lifestyle changes during the trial.

9. Consent to the study and willing to comply with all its procedures.

10. Chronic therapies (if not related to the gastroenterological pathologies object of the study, according to the opinion of Investigator) are allowed, if the regimen is maintained stable during the whole study.

Exclusion Criteria:

1. Patients with heartburn/epigastric pain who have not previously responded to antacid or PPI.

2. Patients having a VAS score > 70mm (VAS related to heartburn/ epigastric pain) for at least 6 out of 14 days preceding the screening visit.

3. Patient presenting one of the following condition:

1. anemia;

2. chronic gastrointestinal bleeding;

3. antibiotic use, including antifungal and antimalarial medication within 2 months preceding the start of the study;

4. progressive unintentional weight loss;

5. persistent or recurrent vomiting;

6. epigastric mass;

7. acute episode with dyspnea, diaphoresis, or tachycardia;

8. anorexia;

9. nausea or vomiting;

10. dysphagia or odynophagia.

4. Patients under triple therapy or eradication therapy against Helicobacter pylori.

5. Patients using any drugs that could affect symptoms, such as NSAIDS, antacids, anti- secretory agents including proton pump inhibitors (other than the study products) and histamine H2-receptor antagonists or prokinetic or antiulcer agents, gastric mucosal protectants, anticholinergics and/or cholinergic agents. Moreover, the patients will be asked to avoid any drugs of the above mentioned since the beginning of the study (since pre-screening visit) until the end of the study.

6. Patients with the presence of the following conditions: erosive GERD, Barrett's oesophagus or oesophageal stricture, active or healing gastroduodenal ulcer (except scars) or any other GI disease, which is not mentioned in the inclusion criteria; history of gastric, duodenal or esophageal surgery; malignant disease of any kind; gallstone. Any chronic disease that may affect the gastrointestinal upper tract.

7. Patients with clinically significant liver disease (AST/SGOT, ALT/SGPT >2 upper limits of normal).

8. Patients with clinically significant renal disease (serum creatinine >1.5 mg/dl).

9. Patient having any other conditions or disease that the Investigator will consider non-appropriate to the study (any severe disease of another major body system other than GI tract).

10. Patients with porphyria, hypophosphatemia, cachexia.

11. Pregnant or nursing women or women planning to become pregnant during the study.

12. Patients with a history of alcohol or drug abuse.

13. Known hypersensitivity or intolerance to any components of the study products or rescue medication.

14. Subjects presenting contraindications to the study products or rescue medication, according to concerning Summaries of Product Characteristics (SPC), e.g. for omeprazole, patients suffering from rare hereditary problems of fructose intolerance, Glucose Galactose Malabsorption (GGM) or sucrase-isomaltase deficiency.

15. Patients being treated with any drug whose pharmacokinetics can interfere with the intake of omeprazole or magaldrate (e.g., for omeprazole, the active substances known as CYP2C19 or CYP3A4 inhibitors, as clarithromycin and voriconazole, or inductors, as rifampicin and St. John's wort, Hypericum, or both) or with any drug with which omeprazole, neobianacid or magaldrate are able to interact.

16. Patient participating to any investigational drug trial within 4 weeks before screening.

Related Conditions & MeSH terms

• EPS
• GERD

Intervention

Device:
• Neobianacid®
Oral administrations of Neobianacid® (30' after meals and on demand)

Drug:
• Omeprazole 20mg
Daily administration Omeprazole 20mg (per os, 30' before breakfast).

Other:
• Neobianacid® placebo
Oral administrations of Neobianacid® placebo (30' after meals and on demand)
• Omeprazole placebo
Daily administration Omeprazole placebo (per os, 30' before breakfast).

Locations

Country	Name	City	State
Italy	Ospedale Civile San Salvatore	L'Aquila
Italy	Azienda Ospedaliera Santa Maria Goretti	Latina	Rome
Italy	Policlinico San Matteo Pavia Fondazione IRCCS	Pavia
Italy	Azienda Ospedaliera Perugia	Perugia
Italy	Azienda Ospedaliera Sant'Andrea	Rome
Italy	Ospedale San Giovanni Addolorata	Rome
Italy	Ospedale Sandro Pertini	Rome
Italy	Ospedale Sant'Eugenio	Rome
Italy	Policlinico Umberto I	Rome
Italy	Policlinico Universitario A. Gemelli	Rome
Italy	Policlinico Universitario Campus Biomedico di Roma	Rome
Italy	Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi d'Aragona	Salerno

Sponsors (4)

Lead Sponsor	Collaborator
Aboca Spa Societa' Agricola	BMR Genomics, Doppel Farmaceutici, University of Roma La Sapienza

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	intestinal microbiota characterization	Characterization of the whole intestinal microbiota carried out by means of the analysis of faecal samples; Baseline and Day 28.	Day-1 and Day28
Primary	Heartburn or epigastric pain severity through treatment (Day-1 to Day13)	Comparison of heartburn or epigastric pain severity by means of a 100mm VAS scale (from "no symptoms" to "overwhelming symptoms"); from Baseline to Day 13, between groups. Baseline is defined as Day -1	Day-1 to Day13
Secondary	Heartburn or epigastric pain severity through treatment (Day-1 to Day7)	Comparison of heartburn or epigastric pain severity by means of a 100mm VAS scale (from "no symptoms" to "overwhelming symptoms") from Baseline to Day 1, Day 3 and Day 7, between groups	Day-1 to Day7
Secondary	Heartburn or epigastric pain severity through treatment (Day14 to Day27)	Assessment of heartburn or epigastric pain severity by means of a 100mm VAS scale (from "no symptoms" to "overwhelming symptoms"); from Day 14 to Day 27 between groups.	Day14 to Day27
Secondary	Assessment of of rescue medication use	Assessment of use (starting date and quantity) of rescue medication (antacid); from Baseline to Day 13, from Day 14 to Day 27 and from Day 28 to Day 55, between groups.	Day-1 to Day55
Secondary	Tablets of Neobianacid® Vs. Neobianacid® placebo Day14 to Day27	Assessment of number of tablets of Neobianacid® on demand in comparison to Neobianacid® placebo on demand; from Day 14 to Day 27, between groups.	Day14 to Day27
Secondary	Tablets of Neobianacid® Vs. Neobianacid® placebo Day28 to Day55	Assessment of number of tablets of Neobianacid® on demand; from Day 28 to Day 55, between groups.	Day28 to Day55
Secondary	Improvement in symptomatology	Improvement in symptomatology, by means of Gastrointestinal Symptom Rating Scale Questionnaire - GSRS; Day 14, Day 28 and Day 56 versus Baseline, between groups.	Day-1 to Day56
Secondary	Improvement in quality of life	Improvement in quality of life, by means of Gastrointestinal Quality of Life Index - GIQLI questionnaire; Day 14, Day 28 and Day 56 versus Baseline, between groups.	Day-1 to Day56
Secondary	Evaluation of treatment	Evaluation of treatment by means of Overall Treatment Evaluation - OTE; Day 14, 28 and 56, between groups.	Day-1 to Day56